What patents cover Crysvita (burosumab), and who owns them?
Crysvita is the brand name for burosumab, a monoclonal antibody. Patent protection for Crysvita is typically split across multiple families: inventions covering the antibody itself, its production/manufacturing, dosing/regimens, and any later improvements or new uses. The company commercializing Crysvita in most markets has been Alexion/AstraZeneca and partners, but the specific assignees and which jurisdictions they hold patents in depends on the country and patent family.
Because patent coverage is territory-specific and changes as patents expire or are challenged, users usually confirm details by checking the patent register or a patent database for the exact assignee and publication numbers.
When do Crysvita patents expire?
Crysvita’s patent expiry is not a single date. It comes as the last remaining protection across each patent family in each country, and may differ due to:
- priority dates (how the earliest application is counted),
- patent term calculations by jurisdiction,
- any patent term extensions (where available),
- and litigation outcomes that can change what remains enforceable.
A precise expiry date for “the” Crysvita patent requires identifying the specific patent number or publication and the jurisdiction (e.g., US vs. EU vs. UK vs. Japan). Without that, only broad guidance is possible: exclusivity typically ends later than the first patent filing, with later-filed improvements potentially extending protection.
Can a generic or biosimilar of Crysvita enter before all patents expire?
Crysvita is a biologic (a monoclonal antibody), so “generic” usually means a biosimilar pathway rather than true small-molecule generic substitution. Even if some patents expire, a biosimilar/bioequivalent may still be blocked by remaining patents covering the product, manufacture, or specific treatment claims.
In practice, developers track:
- the earliest expiring patents,
- the “most important” remaining patents asserted in a given market,
- regulatory reference products and biosimilar approval requirements,
- and any court rulings that narrow or invalidate claims.
Why do people search “Crysvita patent” alongside biosimilar challenges?
Searchers often want to know whether a biosimilar competitor can launch soon or whether litigation is expected to delay entry. Patent disputes in biologics commonly focus on whether the biosimilar infringes specific claims and whether patents are valid. The outcome controls launch timing more than the existence of other, already-expired patents.
What to check if you need the exact Crysvita patent numbers and dates
To get the real expiry timeline (and which patents matter), you’ll usually want to look up:
- the specific patent or application publication number you care about (not just “Crysvita patent”),
- the country/jurisdiction,
- the assignee (company owner),
- and whether there are listed term extensions or active litigation.
If you tell me the country (US, EU, UK, etc.) and whether you mean “the first patent,” “the last patent,” or a specific patent number, I can help narrow what to search for and how to interpret the expiry and enforceability.
---
Sources
None provided.